Contrast-enhanced MRI in Children 2 Months to <2 Years

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to < 2 years of age

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Age: 2 months to < 2 years (23 months)

• Participants (male/female) who are scheduled to undergo gadolinium-enhanced MRI

• Able to comply with the study procedures

Exclusion Criteria:

• Clinical unstable participants (eg, intensive care unit)

• Renal Insufficiency

• Participants undergoing chemotherapythe administration of Magnevist.